Rectal microbicides: Can we make them and will people use them?

AIDS and Behavior

Volumn 15, Issue SUPPL. 1, 2011, Pages

  McGowan, Ian ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; HIV prevention; Microbicides; Rectal

Indexed keywords

ANTIINFECTIVE AGENT;

ARTICLE; DRUG DESIGN; DRUG DEVELOPMENT; FEMALE; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; RECTAL DRUG ADMINISTRATION;

ADMINISTRATION, RECTAL; ANTI-INFECTIVE AGENTS; DRUG DESIGN; DRUG DISCOVERY; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE;

EID: 79955653343     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-011-9899-9     Document Type: Article

References (47)

1. McGowan I. Microbicides for HIV prevention: reality or hope? Curr Opin Infect Dis. 2010;23(1):26-31.
2. Stein ZA. HIV prevention: the need for methods women can use. Am J Public Health. 1990;80(4):460-2. (Pubitemid 20105954)
3. Carlos JA, Bingham TA, Stueve A, et al. The role of peer support on condom use among Black and Latino MSM in three urban areas. AIDS Educ Prev. 2010;22(5):430-44.
4. Gorbach PM, Manhart LE, Hess KL, Stoner BP, Martin DH, Holmes KK. Anal intercourse among young heterosexuals in three sexually transmitted disease clinics in the United States. Sex Transm Dis. 2009;36(4):193-8.
5. Beyrer C. Global prevention of HIV infection for neglected populations: men who have sex with men. Clin Infect Dis. 2010;50(Suppl 3):S108-13.
6. Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol. 1998;148(1):88-96. (Pubitemid 28317549)
7. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol. 1999;150(3):306-11. (Pubitemid 29344958)
8. Mosher WD, Chandra A, Jones J. Sexual behavior and selected health measures: men and women 15- 44 years of age, United States, 2002. Hyattsville, MD: National Center for Health Statistics; 2005 (Sep 15. Report No.: 362).
9. Misegades L, Page-Shafer K, Halperin D, McFarland W. Anal intercourse among young low-income women in California: an overlooked risk factor for HIV? AIDS. 2001;15(4):534-5. (Pubitemid 32207578)
10. Karim SS, Ramjee G. Anal sex and HIV transmission in women. Am J Public Health. 1998;88(8):1265-6.
11. Lane T, Pettifor A, Pascoe S, Fiamma A, Rees H. Heterosexual anal intercourse increases risk of HIV infection among young South African men. AIDS. 2006;20(1):123-5. (Pubitemid 41818125)
12. Kalichman S, Simbayi L, Cain D, Jooste S. Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa. Sex Transm Infect. 2009;85(6):411-5.
13. Baral S, Trapence G, Motimedi F, et al. HIV prevalence, risks for HIV infection, and human rights among men who have sex with men (MSM) in Malawi, Namibia, and Botswana. PLoS ONE. 2009;4(3):e4997.
14. Baral S, Sifakis F, Cleghorn F, Beyrer C. Elevated risk for HIV infection among men who have sex with men in low- and middleincome countries 2000-2006: a systematic review. PLoS Med. 2007;4(12):e339.
15. Carballo-Dieguez A, Stein Z, Saez H, Dolezal C, Nieves-Rosa L, Diaz F. Frequent use of lubricants for anal sex among men who have sex with men: the HIV prevention potential of a microbicidal gel. Am J Public Health. 2000;90(7):1117-21. (Pubitemid 30445367)
16. Gross M, Buchbinder SP, Celum C, Heagerty P, Seage GR III. Rectal microbicides for U.S. gay men. Are clinical trials needed? Are they feasible? HIVNET Vaccine Preparedness Study Protocol Team. Sex Transm Dis. 1998;25(6):296-302. (Pubitemid 28309067)
17. Carballo-Dieguez A, O'sullivan LF, Lin P, Dolezal C, Pollack L, Catania J. Awareness and attitudes regarding microbicides and nonoxynol-9 use in a probability sample of gay men. AIDS Behav. 2007;11(2):271-6.
18. Nodin N, Carballo-Dieguez A, Ventuneac AM, Balan IC, Remien R. Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care. 2008;20(1):106-15. (Pubitemid 351264545)
19. Berg RC. Barebacking: a review of the literature. Arch Sex Behav. 2009;38(5):754-64.
20. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL- 1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360(9338):971-7. (Pubitemid 35284107)
21. Karim QA, Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-74.
22. Tabet SR, Surawicz C, Horton S, et al. Safety and toxicity of nonoxynol-9 gel as a rectal microbicide. Sex Transm Infect. 1999;26(10):564-71. (Pubitemid 29523379)
23. McGowan I, Elliott J, Cortina G, et al. Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J Acquir Immune Defic Syndr. 2007;46(4): 417-25. (Pubitemid 350098692)
24. Anton P, Adler A, Khanukova E, et al. A Phase 1 rectal safety and acceptability study of UC781 microbicide gel. In: 16th Conference on Retroviruses and opportunistic infections, Montreal, 2009 (abstract 1066).
25. Fuchs EJ, Lee LA, Torbenson MS, et al. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis. 2007;195(5): 703-10.
26. Barnhart KT, Pretorius ES, Timbers K, Shera D, Shabbout M, Malamud D. In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraception. 2004;70(6):498-505. (Pubitemid 39488208)
27. Barnhart K, Kulp JL, Rosen M, Shera DM. A randomized trial to determine the distribution of four topical gel formulations in the human vagina. Contraception. 2009;79(4):297-303.
28. Hendrix CW, Fuchs EJ, Macura KJ, Lee LA, Parsons TL, Bakshi RP, et al. Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates. Clin Pharmacol Ther. 2008;83(1):97-105.
29. UNAIDS. Ethical considerations in biomedical HIV prevention trials. Joint United Nations Programme on HIV/AIDS (UNAIDS); 2007.http://data.unaids.org/pub/ Report/2007/jc1399-ethical-considerations-en.pdf. Accessed 31 Oct 2010.
30. Elias C, Coggins C. Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: Where have we been? Where are we going? J Womens Health Gend Based Med. 2001;10(2):163-73. (Pubitemid 32243836)
31. Severy L, Newcomer S. Critical issues in contraceptive and STI acceptability research. J Soc Issues. 2005;61(1):45-65. (Pubitemid 40427302)
32. Mantell JE, Myer L, Carballo-Dieguez A, Stein Z, Ramjee G, Morar NS, et al. Microbicide acceptability research: current approaches and future directions. Soc Sci Med. 2005;60(2): 319-30. (Pubitemid 39452548)
33. Morrow KM, Ruiz MS. Assessing microbicide acceptability: a comprehensive and integrated approach. AIDS Behav. 2008;12(2):272-83. (Pubitemid 351643035)
34. Tolley EE, Severy LJ. Integrating behavioral and social science research into microbicide clinical trials: challenges and opportunities. Am J Public Health. 2006;96(1):79-83. (Pubitemid 43042836)
35. Rosen RK, Morrow KM, Carballo-Dieguez A, et al. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J Womens Health (Larchmt). 2008;17(3):383-92. (Pubitemid 351457833)
36. Bentley ME, Morrow KM, Fullem A, et al. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plann Perspect. 2000;32(4):184-8. (Pubitemid 30616538)
37. Morrow K, Rosen R, Richter L, et al. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J Womens Health (Larchmt). 2003;12(7):655-66. (Pubitemid 37266008)
38. El-Sadr WM, Mayer KH, Maslankowski L, et al. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIVinfected women. AIDS. 2006;20(8):1109-16. (Pubitemid 43786098)
39. Carballo-Dieguez A, Exner T, Dolezal C, Pickard R, Lin P, Mayer KH. Rectal microbicide acceptability: results of a volume escalation trial. Sex Transm Dis. 2007;34(4):224-9. (Pubitemid 46606747)
40. Carballo-Dieguez A, Dolezal C, Bauermeister JA, O'Brien W, Ventuneac A, Mayer K. Preference for gel over suppository as delivery vehicle for a rectal microbicide: results of a randomised, crossover acceptability trial among men who have sex with men. Sex Transm Infect. 2008;84(6):483-7.
41. Ventuneac A, Carballo-Dieguez A, McGowan I, et al. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men. AIDS Behav. 2010;14(3):618-28.
42. Rudy BJ, Kapogiannis BG, Lally MA, et al. Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials. J Acquir Immune Defic Syndr. 2010;54(Suppl 1):S31-S42.
43. van Griensven F, de Lind van Wijngaarden JW, Baral S, Grulich A. The global epidemic of HIV infection among men who have sex with men. Curr Opin HIV AIDS. 2009 Jul;4(4):300-7.
44. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209-20.
45. Elliott J, McGowan I, Adler A, et al. Strong suppression of HIV-1 infection of colorectal explants following in vivo rectal application of UC781 gel: a novel endpoint in a Phase I trial. In: 16th Conference on Retroviruses and opportunistic infections, Montreal, 2009 (abstract 1067).
46. Sifakis F, Hylton JB, Flynn C, et al. Racial disparities in HIV incidence among young men who have sex with men: the Baltimore Young Men's Survey. J Acquir Immune Defic Syndr. 2007;46(3):343-8. (Pubitemid 350287364)
47. Sifakis F, Hylton JB, Flynn C, et al. Prevalence of HIV infection and prior HIV testing among young men who have sex with men. The Baltimore young men's survey. AIDS Behav. 2010;14(4): 904-12.